Celldex Therapeutics CLDX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's retained earnings?
- Celldex Therapeutics (CLDX) reported retained earnings of -$1.89B in Q1 2026.
- How has Celldex Therapeutics's retained earnings changed year-over-year?
- Celldex Therapeutics's retained earnings decreased by 17.6% year-over-year, from -$1.61B to -$1.89B.
- What is the long-term trend for Celldex Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Celldex Therapeutics's retained earnings has grown at a 11.1% compound annual growth rate (CAGR), from -$1.07B to -$1.81B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.